• In 50 out of 63 patients (79%) who responded to LIBTAYO, the response lasted 6 months or longer
• In 34 out of 63 patients (54%) who responded to LIBTAYO, the response lasted 12 months or longer

In the same clinical trial, in a separate group of 56 patients with CSCC that had spread who took LIBTAYO at the recommended dose^†:

• 23 out of 56 patients (41%) saw an improvement in their advanced CSCC
  • 20 out of 56 patients (36%) saw tumors shrink (partial response)
  • 3 out of 56 patients (5%) saw tumors disappear completely (complete response)
  • In 15 out of 23 patients (65%) who responded to LIBTAYO, the response lasted 6 months or longer

In a different clinical trial of 26 patients with CSCC that had spread or could not be cured by surgery or radiation*:

• 13 out of 26 patients (50%) saw tumors shrink (all partial responses)
  • In 11 out of 13 patients (85%) who responded to LIBTAYO, the response lasted 6 months or longer

In these trials, responses lasted between 1 month and more than 2 years (24.2+ months); plus sign (+) means the patient was still responding to treatment at their last assessment.

LIBTAYO may not work for everyone.

*Patients were dosed by body weight.

^†LIBTAYO 350 mg over a 30-minute infusion every 3 weeks.